Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)

[1]  A. Azmi,et al.  An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals , 2009, Molecular Cancer.

[2]  G. Rassidakis,et al.  The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53 , 2009, Leukemia.

[3]  Mark W Lowdell,et al.  2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. , 2009, Blood.

[4]  J. Garibal,et al.  Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein–Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells , 2009, Leukemia.

[5]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[6]  M. Raffeld,et al.  MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma , 2009, Clinical Cancer Research.

[7]  M. Andreeff,et al.  Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma , 2009, Leukemia.

[8]  L. Vassilev,et al.  p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. , 2008, Blood.

[9]  F. McCormick,et al.  E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines , 2008, Oncogene.

[10]  K. Young,et al.  Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma , 2008, Clinical Cancer Research.

[11]  E. Morselli,et al.  Targeting p53 to mitochondria for cancer therapy , 2008, Cell cycle.

[12]  G. Wahl,et al.  BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death , 2008, Cell cycle.

[13]  S. Keir,et al.  Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[14]  H. Findley,et al.  MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2 , 2008, Leukemia.

[15]  X. Zhao,et al.  HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function , 2008, Oncogene.

[16]  K. Elenitoba-Johnson,et al.  NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. , 2007, Blood.

[17]  Annegien Broeks,et al.  In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. , 2007, Blood.

[18]  L. Jeffrey Medeiros,et al.  Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma , 2007, Clinical Cancer Research.

[19]  L. Vassilev,et al.  Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1 , 2007, Oncogene.

[20]  S. Kurki,et al.  Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. , 2007, The Journal of clinical investigation.

[21]  L. Vassilev,et al.  Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells , 2007, Leukemia.

[22]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[23]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[24]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[25]  M. Konopleva,et al.  Concomitant Inhibition of MDM2 and Bcl-2 Protein Function Synergistically Induce Mitochondrial Apoptosis in AML , 2006, Cell cycle.

[26]  Marina Konopleva,et al.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. , 2006, Blood.

[27]  Roger M Macklis,et al.  Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation , 2006, Nature chemical biology.

[28]  Fengqin Gao,et al.  Bcl2's Flexible Loop Domain Regulates p53 Binding and Survival , 2006, Molecular and Cellular Biology.

[29]  Gabriel Pons,et al.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.

[30]  R. Fanin,et al.  Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) , 2006 .

[31]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Konopleva,et al.  Mdm 2 inhibitor Nutlin-3 a induces p 53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to Fludarabine in chronic lymphocytic leukemia , 2006 .

[33]  L. Vassilev,et al.  Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. , 2005, Blood.

[34]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[35]  T. Kuwana,et al.  PUMA Couples the Nuclear and Cytoplasmic Proapoptotic Function of p53 , 2005, Science.

[36]  M. Calaminici,et al.  A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma , 2005, Leukemia.

[37]  D. de Jong.  Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  John Calvin Reed,et al.  Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy. , 2004, Current pharmaceutical design.

[39]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[40]  Ash A. Alizadeh,et al.  Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. , 2003, Blood.

[41]  W. May,et al.  Phosphorylation of Bcl2 and regulation of apoptosis , 2001, Leukemia.

[42]  Y. Furukawa,et al.  Phosphorylation of Bcl-2 Protein by CDC2 Kinase during G2/M Phases and Its Role in Cell Cycle Regulation* , 2000, The Journal of Biological Chemistry.

[43]  M V Chernov,et al.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.

[44]  D. Louis,et al.  Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma , 1999, Leukemia.

[45]  P. G. Tyler,et al.  Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. , 1994, The Journal of biological chemistry.

[46]  D. Longo,et al.  p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.

[47]  K. Offit,et al.  p53 mutations are associated with histologic transformation of follicular lymphoma. , 1993, Blood.

[48]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[49]  F. Cabanillas,et al.  Establishment and characterization of human B-cell lymphoma cell lines using B-cell growth factor. , 1990, Blood.

[50]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.